Details of the Drug

General Information of Drug (ID: DMG3Y89)

Drug Name
Trabectedin
Synonyms Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Ovarian cancer 2C73 Phase 3 [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 761.8
Topological Polar Surface Area (xlogp) 3.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 15
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 33 - 50 hours [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 25 L/kg [4]
Chemical Identifiers
Formula
C39H43N3O11S
IUPAC Name
[(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
Canonical SMILES
CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O
InChI
InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
InChIKey
PKVRCIRHQMSYJX-AIFWHQITSA-N
Cross-matching ID
PubChem CID
108150
ChEBI ID
CHEBI:84050
CAS Number
114899-77-3
DrugBank ID
DB05109
TTD ID
D03RTK
INTEDE ID
DR1625
ACDINA ID
D01496

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [5]
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [5]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [5]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trabectedin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [59]
Armodafinil DMGB035 Moderate Increased metabolism of Trabectedin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
LEE011 DMMX75K Moderate Decreased metabolism of Trabectedin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [59]
Coadministration of a Drug Treating the Disease Different from Trabectedin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [60]
Metreleptin DM1NOEK Moderate Increased metabolism of Trabectedin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [59]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Trabectedin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [59]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Tagraxofusp. Acute myeloid leukaemia [2A60] [59]
Arn-509 DMT81LZ Major Increased metabolism of Trabectedin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [59]
Gilteritinib DMWQ4MZ Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Gilteritinib. Acute myeloid leukaemia [2A60] [59]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Inotersen. Amyloidosis [5D00] [59]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [61]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Oxymetholone. Aplastic anaemia [3A70] [59]
Troleandomycin DMUZNIG Major Decreased metabolism of Trabectedin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [60]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Trabectedin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [62]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and LY2835219. Breast cancer [2C60-2C6Y] [59]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Pralatrexate. Breast cancer [2C60-2C6Y] [59]
Tucatinib DMBESUA Major Decreased metabolism of Trabectedin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Palbociclib DMD7L94 Moderate Decreased metabolism of Trabectedin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [59]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Macitentan. Cardiovascular disease [BA00-BE2Z] [59]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Chenodiol. Cholelithiasis [DC11] [59]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Regorafenib. Colorectal cancer [2B91] [59]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Intedanib. Colorectal cancer [2B91] [59]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Pasireotide. Cushing syndrome [5A70] [59]
Lumacaftor DMCLWDJ Major Increased metabolism of Trabectedin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [59]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Trabectedin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [59]
MK-8228 DMOB58Q Moderate Decreased metabolism of Trabectedin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [59]
Cenobamate DMGOVHA Moderate Increased metabolism of Trabectedin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Stiripentol DMMSDOY Moderate Decreased metabolism of Trabectedin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Cannabidiol. Epileptic encephalopathy [8A62] [59]
Tazemetostat DMWP1BH Moderate Increased metabolism of Trabectedin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [59]
Boceprevir DMBSHMF Major Decreased metabolism of Trabectedin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [60]
Telaprevir DMMRV29 Major Decreased metabolism of Trabectedin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [60]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [59]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [63]
Cobicistat DM6L4H2 Major Decreased metabolism of Trabectedin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Etravirine DMGV8QU Moderate Increased metabolism of Trabectedin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [59]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Trabectedin and Mipomersen. Hyper-lipoproteinaemia [5C80] [64]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Trabectedin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [65]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Trabectedin and BMS-201038. Hyper-lipoproteinaemia [5C80] [66]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [59]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [59]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Trabectedin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [59]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Trabectedin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [59]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Trabectedin and Denosumab. Low bone mass disorder [FB83] [67]
Crizotinib DM4F29C Moderate Decreased metabolism of Trabectedin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [59]
Ceritinib DMB920Z Major Decreased metabolism of Trabectedin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [60]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Lurbinectedin. Lung cancer [2C25] [59]
PF-06463922 DMKM7EW Moderate Increased metabolism of Trabectedin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and BIBW 2992. Lung cancer [2C25] [59]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Pralsetinib. Lung cancer [2C25] [59]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Capmatinib. Lung cancer [2C25] [59]
Selpercatinib DMZR15V Moderate Decreased metabolism of Trabectedin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [59]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [59]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [59]
Idelalisib DM602WT Major Decreased metabolism of Trabectedin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [60]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and IPI-145. Mature B-cell leukaemia [2A82] [59]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Blinatumomab. Mature B-cell lymphoma [2A85] [59]
Ponatinib DMYGJQO Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Ponatinib. Mature B-cell lymphoma [2A85] [59]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Arry-162. Melanoma [2C30] [59]
Vemurafenib DM62UG5 Moderate Increased metabolism of Trabectedin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [59]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Ipilimumab. Melanoma [2C30] [59]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Trabectedin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [59]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Carfilzomib. Multiple myeloma [2A83] [59]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Panobinostat. Multiple myeloma [2A83] [59]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Elotuzumab. Multiple myeloma [2A83] [59]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Tecfidera. Multiple sclerosis [8A40] [59]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Trabectedin and Siponimod. Multiple sclerosis [8A40] [60]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Trabectedin and Fingolimod. Multiple sclerosis [8A40] [68]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Trabectedin and Ocrelizumab. Multiple sclerosis [8A40] [69]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Trabectedin and Ozanimod. Multiple sclerosis [8A40] [59]
Fedratinib DM4ZBK6 Moderate Increased metabolism of Trabectedin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [59]
Netupitant DMEKAYI Moderate Decreased metabolism of Trabectedin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [59]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Entrectinib. Non-small cell lung cancer [2C25] [59]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Trabectedin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [59]
Abametapir DM2RX0I Moderate Decreased metabolism of Trabectedin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [70]
Lefamulin DME6G97 Moderate Decreased metabolism of Trabectedin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [71]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Trabectedin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [60]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and ABIRATERONE. Prostate cancer [2C82] [59]
Enzalutamide DMGL19D Major Increased metabolism of Trabectedin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [59]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Ambrisentan. Pulmonary hypertension [BB01] [59]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Axitinib. Renal cell carcinoma [2C90] [59]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Tocilizumab. Rheumatoid arthritis [FA20] [59]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Trabectedin and Canakinumab. Rheumatoid arthritis [FA20] [72]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Trabectedin and Rilonacept. Rheumatoid arthritis [FA20] [72]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Trabectedin and Golimumab. Rheumatoid arthritis [FA20] [73]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Sarilumab. Rheumatoid arthritis [FA20] [59]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Trabectedin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [74]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Trabectedin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [59]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Trabectedin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [59]
Brilinta DMBR01X Moderate Decreased metabolism of Trabectedin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [59]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Lenvatinib. Thyroid cancer [2D10] [59]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Trabectedin and Elagolix. Uterine fibroid [2E86] [59]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Phosphoric acid E00039 1004 Acidulant; Buffering agent
Potassium phosphate monobasic E00429 516951 Buffering agent
Potassium hydroxide E00233 14797 Alkalizing agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trabectedin 1mg/vial powder 1mg/vial Powder Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2774).
2 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
16 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
17 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
18 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
19 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
20 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
21 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
22 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
23 Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
24 Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
25 Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
26 Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
27 Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
28 Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
29 Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
30 Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
31 Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
32 Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
33 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
34 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
35 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
36 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
37 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
38 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
39 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
40 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
41 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
42 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
43 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
44 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
45 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
46 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
47 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
48 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
49 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
50 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
51 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
52 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
53 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
54 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
55 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
56 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
57 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
59 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
60 Cerner Multum, Inc. "Australian Product Information.".
61 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
62 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
63 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
64 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
65 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
66 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
67 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
68 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
70 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
71 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
72 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
73 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
74 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]